Equities analysts expect Shire PLC (NASDAQ:SHPG) to post sales of $3.75 billion for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Shire PLC’s earnings, with the lowest sales estimate coming in at $3.70 billion and the highest estimate coming in at $3.81 billion. Shire PLC reported sales of $2.43 billion during the same quarter last year, which would suggest a positive year over year growth rate of 54.3%. The firm is scheduled to report its next earnings report before the market opens on Thursday, August 3rd.
On average, analysts expect that Shire PLC will report full year sales of $3.75 billion for the current year, with estimates ranging from $15.07 billion to $15.41 billion. For the next year, analysts expect that the company will post sales of $16.38 billion per share, with estimates ranging from $15.69 billion to $17.05 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Shire PLC.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a return on equity of 13.05% and a net margin of 2.14%. The firm’s revenue was up 109.0% on a year-over-year basis. During the same period last year, the company earned $2.12 earnings per share.
SHPG has been the topic of a number of recent analyst reports. Royal Bank Of Canada set a $218.00 price target on Shire PLC and gave the company a “buy” rating in a report on Thursday, June 8th. Jefferies Group LLC set a $239.00 price target on Shire PLC and gave the company a “buy” rating in a report on Saturday, March 18th. Stifel Nicolaus cut their price target on Shire PLC from $250.00 to $245.00 and set a “buy” rating on the stock in a report on Friday, June 9th. Cantor Fitzgerald set a $222.00 price target on Shire PLC and gave the company a “buy” rating in a report on Saturday, July 1st. Finally, ValuEngine raised Shire PLC from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seventeen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $227.45.
ILLEGAL ACTIVITY NOTICE: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://sportsperspectives.com/2017/08/10/shire-plc-shpg-expected-to-post-quarterly-sales-of-3-75-billion-updated-updated-updated.html.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares in the last quarter. Glenview Capital Management LLC bought a new position in Shire PLC during the first quarter valued at about $176,927,000. Boston Partners boosted its position in Shire PLC by 80.7% in the first quarter. Boston Partners now owns 1,359,151 shares of the biopharmaceutical company’s stock valued at $236,805,000 after buying an additional 606,814 shares in the last quarter. Jana Partners LLC bought a new position in Shire PLC during the first quarter valued at about $94,903,000. Finally, New South Capital Management Inc. bought a new position in Shire PLC during the first quarter valued at about $87,954,000. 20.89% of the stock is currently owned by institutional investors.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.